Cronos (CRON) Net Equity Issued and Repurchased (2019)

Cronos' (CRON) quarterly Net Equity Issued and Repurchased came in at $1.8 billion in Q1 2019.

Cronos (CRON) Net Equity Issued and Repurchased (2019) Analysis & Trends

Cronos' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $1.8 billion for Q1 2019.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $1.8 billion in Q1 2019; TTM through Dec 2019 was $1.8 billion, a N/A change from a year earlier, with the FY2019 full-year figure at $1.8 billion, changed N/A from the prior year.
Net Equity Issued and Repurchased held at $1.8 billion in Q1 2019 per CRON's latest filing.
Across five years, Net Equity Issued and Repurchased topped out at $1.8 billion in Q1 2019 and bottomed at $1.8 billion in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	500,000.00
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	23.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Cronos	1.04 Bn	267.78 Mn	19.15 Mn	-

Download Data

Date	Value
Mar 31, 2019	1.81 Bn
Mar 31, 2019	1.81 Bn